This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hojo, S. Articles by Saiki, I. Search for Related Content PubMed Articles by Hojo, S. Articles by Saiki, I.

High-Level Expression of Chemokine CXCL16 by Tumor Cells Correlates with a Good Prognosis and Increased Tumor-Infiltrating Lymphocytes in Colorectal Cancer

¹ Department of Surgery (II), Faculty of Medicine, ² Division of Pathogenic Biochemistry, Institute of Natural Medicine, ³ Department of Pathology (I), Faculty of Medicine, ⁴ The 21st Century COE Program, University of Toyama, Toyama, Japan and ⁵ Department of Microbiology and Solution Oriented Research for Science and Technology, Kinki University School of Medicine, Osaka, Japan

Requests for reprints: Keiichi Koizumi, Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, Toyama 930-0194, Japan. Phone: 81-76-434-7621; E-mail: kkoizumi{at}inm.u-toyama.ac.jp.

CXCL16 is a new member of the chemokine superfamily, which exists in a transmembrane as well as a soluble form. Its receptor CXCR6 is detected on CD4⁺ T cells, CD8⁺ T cells, and natural killer T cells. Here, we report a significant correlation of CXCL16 expression by tumor cells with the infiltration of T cells and prognosis in colorectal cancer (CRC). We first found that CXCL16 expression was consistently up-regulated more in tumor tissues than in normal mucosa derived from the same CRC patients. Four human CRC cell lines also expressed CXCL16 mRNA and secreted soluble CXCL16. We next examined the expression of CXCL16 and infiltration of lymphocytes in CRC specimens (n = 58) by immunohistochemistry. CRC patients with high levels of CXCL16 expression (n = 43) had higher levels of CD4⁺ and CD8⁺ tumor-infiltrating lymphocytes (TIL; P < 0.01) than those with low levels of CXCL16 expression (n = 15). Furthermore, the high CXCL16 expression group showed significantly better prognosis than the low CXCL16 expression group (P < 0.05). Collectively, our data suggest that the expression of CXCL16 by tumor cells enhances the recruitment of TILs, thereby bringing about a better prognosis in CRC. Thus, CXCL16 is a new prognostic biomarker and may be useful for the development of a more effective therapeutic strategy for CRC. [Cancer Res 2007;67(10):4725–31]

This article has been cited by other articles:

				S. Ogino, K. Nosho, N. Irahara, J. A. Meyerhardt, Y. Baba, K. Shima, J. N. Glickman, C. R. Ferrone, M. Mino-Kenudson, N. Tanaka, et al. Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype Clin. Cancer Res., October 15, 2009; 15(20): 6412 - 6420. [Abstract] [Full Text] [PDF]

				P. Gutwein, M. S. Abdel-Bakky, A. Schramme, K. Doberstein, N. Kampfer-Kolb, K. Amann, I. A. Hauser, N. Obermuller, C. Bartel, A.-A. H. Abdel-Aziz, et al. CXCL16 Is Expressed in Podocytes and Acts as a Scavenger Receptor for Oxidized Low-Density Lipoprotein Am. J. Pathol., June 1, 2009; 174(6): 2061 - 2072. [Abstract] [Full Text] [PDF]

				S.-Y. Sung, C.-L. Hsieh, A. Law, H. E. Zhau, S. Pathak, A. S. Multani, S. Lim, I. M. Coleman, L.-C. Wu, W. D. Figg, et al. Coevolution of Prostate Cancer and Bone Stroma in Three-Dimensional Coculture: Implications for Cancer Growth and Metastasis Cancer Res., December 1, 2008; 68(23): 9996 - 10003. [Abstract] [Full Text] [PDF]

				S. Matsumura, B. Wang, N. Kawashima, S. Braunstein, M. Badura, T. O. Cameron, J. S. Babb, R. J. Schneider, S. C. Formenti, M. L. Dustin, et al. Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells J. Immunol., September 1, 2008; 181(5): 3099 - 3107. [Abstract] [Full Text] [PDF]

				J. Meijer, J. Ogink, B. Kreike, D. Nuyten, K. E. de Visser, and E. Roos The Chemokine Receptor CXCR6 and Its Ligand CXCL16 Are Expressed in Carcinomas and Inhibit Proliferation Cancer Res., June 15, 2008; 68(12): 4701 - 4708. [Abstract] [Full Text] [PDF]

				F. M. Speetjens, P. J.K. Kuppen, M. H. Sandel, A. G. Menon, D. Burg, C. J.H. van de Velde, R. A.E.M. Tollenaar, H. J.G.M. de Bont, and J. F. Nagelkerke Disrupted Expression of CXCL5 in Colorectal Cancer Is Associated with Rapid Tumor Formation in Rats and Poor Prognosis in Patients Clin. Cancer Res., April 15, 2008; 14(8): 2276 - 2284. [Abstract] [Full Text] [PDF]